NCT05476770: Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies |
|
|
| Recruiting | 1 | 54 | US, RoW | Tagraxofusp, Elzonris, Fludarabine, Cytarabine, Cytosar, Dexamethasone, Decadron, Vincristine, Oncovin, Azacitidine, AZA, Vidaza, Methotrexate, MTX, Amethopterin, Cytarabine IT, Hydrocortisone | Therapeutic Advances in Childhood Leukemia Consortium | Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia | 11/25 | 11/27 | | |
